PRECISION MEDICINE – Page 8 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2019-08-26

Study Reveals Key Differences Between Three Frontline Breast Cancer Drugs

Source Harvard Medical School The findings of a new Harvard Medical School study suggest important differences between three frontline drugs used to treat advanced breast cancer. The researcher’s findings were published in Cell Chemical Biology. The three CDK4/6 inhibitors, abemaciclib, palbociclib, and ribociclib have exhibited exceptional efficacy in hindering breast tumor growth, improving survival rates and prompting FDA approval.

No Comments InCANCER

PIER MARIA FORNASARI
2019-08-25

10 Biopharmaceutical Companies Trying To Cure Cancer

Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated at an astounding $1.11 trillion in size. Every year, billions are spent on the research and development of cancer drugs, with numerous trials conducted in an

No Comments InCANCER

PIER MARIA FORNASARI
2019-08-23

New research published in cancer discovery identifies new drug target for glioblastoma

A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells. While previous research has shown that a protein called

No Comments InCANCER

PIER MARIA FORNASARI
2019-08-22

Precision Medicine Trials and Molecular Testing Guidelines Expand to Reach More Patients

The Lung Cancer Master Protocol (Lung-MAP), a large precision medicine umbrella trial supported by the National Cancer Institute (NCI) and their partners, has opened the trial to include advanced-stage patients with all non–small cell lung cancers (NSCLCs). To accommodate these new trial patients, the NCI has also made further changes to the trial’s protocol. The

No Comments InPRECISION MEDICINE

PIER MARIA FORNASARI
2019-08-20

Sarepta Duchenne drug rejected by FDA in surprise setback

In an unexpected decision, the Food and Drug Administration rejected Sarepta Therapeutics’ experimental drug for Duchenne muscular dystrophy, issuing on Monday a Complete Response Letter to the rare disease biotech. According to Sarepta, the agency cited in its refusal infection risk tied to the drug’s delivery as well as preclinical signs of kidney toxicity. Called

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-08-20

FDA approves entrectinib which targets a key genetic driver of cancer, rather than a specific type of tumour

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to entrectinib, a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments. “We are in an exciting era of innovation in cancer treatment as we

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-06-03

Encouraging early data for Amgen’s BiTE therapies

Amgen has showcased some encouraging early stage data from candidates based on its novel bispecific T cell engager (BiTE) platform at ASCO. Bispecific antibodies are one of the most promising emerging areas in immuno-oncology, with numerous biotechs and pharma companies developing their own variants of the technology. The potential is for the treatments to show

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-04-09

Exosomes:Target for Cancer Immunotherapy

It was once a central tenet of biology that RNA molecules did their work inside the cell. But it’s now clear that RNA molecules are also active outside the cell, with potentially major implications for our health. To learn more about these unrecognized roles, the NIH Common Fund has launched the Extracellular RNA (exRNA) Communication Program. This month,

One comment InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-03-29

Potassium shapes antitumor immunity

A new study led by scientists in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI) sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-03-19

US FDA approves the first immunotherapy for extensive-stage small cell lung cancer

Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) First new initial treatment option approved by the U.S. Food and Drug Administration (FDA) for people with ES-SCLC in more than 20 years Tecentriq in combination with chemotherapy

No Comments InIMMUNOTHERAPY

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category PRECISION MEDICINE

Study Reveals Key Differences Between Three Frontline Breast Cancer Drugs

10 Biopharmaceutical Companies Trying To Cure Cancer

New research published in cancer discovery identifies new drug target for glioblastoma

Precision Medicine Trials and Molecular Testing Guidelines Expand to Reach More Patients

Sarepta Duchenne drug rejected by FDA in surprise setback

FDA approves entrectinib which targets a key genetic driver of cancer, rather than a specific type of tumour

Encouraging early data for Amgen’s BiTE therapies

Exosomes:Target for Cancer Immunotherapy

Potassium shapes antitumor immunity

US FDA approves the first immunotherapy for extensive-stage small cell lung cancer